Last reviewed 2026-04-23 · How we verify

Ig NextGen 10%

Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.

Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins. Used for Primary immunodeficiency disorders, Secondary immunodeficiency conditions, Autoimmune and inflammatory disorders (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy).

At a glance

Mechanism of action

As a next-generation IVIG formulation, it contains polyspecific human immunoglobulins (primarily IgG) derived from pooled plasma donations. It functions through multiple mechanisms including opsonization of pathogens, complement activation, Fc receptor engagement, and immune modulation to treat primary immunodeficiencies and autoimmune/inflammatory conditions.

Approved indications

• Primary immunodeficiency disorders
• Secondary immunodeficiency conditions
• Autoimmune and inflammatory disorders (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)

Common side effects

• Headache
• Fever
• Chills
• Myalgia
• Infusion reactions
• Thromboembolism

Key clinical trials

• Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients (PHASE3)
• Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ig NextGen 10% CI brief — competitive landscape report
• Ig NextGen 10% updates RSS · CI watch RSS
• CSL Limited portfolio CI